A safety and pharmacokinetic trial assessing delivery of dapivirine from a vaginal ring in healthy women
A safety and pharmacokinetic trial assessing delivery of dapivirine from a vaginal ring in healthy women
复制标题
DOI:
10.1097/qad.0000000000000280
复制
发表时间:
2014-06-19
期刊:
影响因子:
3.8
通讯作者:
van Niekerk, Neliette
中科院分区:
文献类型:
--
作者:
Nel, Annalene;Haazen, Wouter;van Niekerk, Neliette
Objectives: Women-initiated HIV-prevention products are urgently needed. To address this need, a trial was conducted to assess the safety and pharmacokinetics of a silicone elastomer matrix vaginal ring containing 25 mg of the antiretroviral drug dapivirine when used continuously for 28 consecutive days.Methods: A double-blind, randomized, placebo-controlled trial was conducted in 16 healthy, HIV-negative women, 18-40 years of age, who were randomized 1 : 1 to use either the active or matching placebo ring for 28 days. Participants were followed during and for 28 days after ring use for safety and pharmacokinetic evaluations.Results: The dapivirine vaginal ring was safe and well tolerated with no differences in safety endpoints between the active and placebo ring. The concentration-time plots of dapivirine in vaginal fluid were indicative of a sustained release of dapivirine over the 28 days of use. Dapivirine vaginal fluid concentrations were highest near the ring, followed by the cervix and introitus (mean C-max of 80, 67 and 31 mu g/g, respectively). Vaginal fluid concentrations of dapivirine on the day of ring removal (day 28) at all three collection sites exceeded by more than 3900-fold the IC99 for dapivirine in a tissue explant infection model. Plasma dapivirine concentrations were low (